ReviewFrontiers in oncology2017
Targeted Therapy for Medullary Thyroid Cancer: A Review.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Multifocality as a marker of aggressiveness in medullary thyroid carcinoma: a retrospective cohort analysis of lymph node metastasis and recurrence.The oncologist · 2026Article
- Individualized survival prediction in medullary thyroid carcinoma using a least absolute shrinkage and selection operator-Cox-based nomogram.The Journal of international medical research · 2026Article
- DNA Damage and Repair in Thyroid Physiology and Disease.Endocrine reviews · 2026Review
- Efficacy and Safety of Pazopanib in the Treatment of Thyroid Cancer: A Systematic Review.Biomedicines · 2024Review
- Voltage-Gated Sodium Channel NaCancers · 2023Article
- Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes.Cancers · 2023Article
- Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009-2022.Drug design, development and therapy · 2023Article
- Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model.Biomedicines · 2022Article
- Metastatic medullary thyroid carcinoma: a new way forward.Endocrine-related cancer · 2022Review
- Multiple endocrine neoplasia 2: an overview.Therapeutic advances in chronic disease · 2022Review
- Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.International journal of molecular sciences · 2021Review
- Encapsulated papillary variant of medullary carcinoma of thyroid with extensive cystic change: an extremely rare presentation.Medicine and pharmacy reports · 2021Article
- Article
- Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences · 2021Article
- Review
- Review
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.Journal of hematology & oncology · 2019Review
- Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients.International journal of endocrinology · 2019Article
- Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences · 2018Review
- ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report.Diseases (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid cancers (MTCs) constitute between 2 and 5% of all thyroid cancers. The 10-year overall survival (OS) rate of patients with localized disease is around 95% while that of patients with regional stage disease is about 75%. Only 20% of patients with distant metastases at diagnosis survive 10 years which is significantly lower than for differentiated thyroid cancers. Cases with regional metastases at presentation have high recurrence rates. Adjuvant external radiation confers local control but not improved OS. The management of residual, recurrent, or metastatic disease till a few years ago was re-surgery with local measures such as radiation. Chemotherapy was used with marginal benefit. The development of targeted therapy has brought in a major advantage in management of such patients. Two drugs-vandetanib and cabozantinib-have been approved for use in progressive or metastatic MTC. In addition, several drugs acting on other steps of the molecular pathway are being investigated with promising results. Targeted radionuclide therapy also provides an effective treatment option with good quality of life. This review covers the rationale of targeted therapy for MTC, present treatment options, drugs and methods under investigation, as well as an outline of the adverse effects and their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.